Figure 1From: Effects on quality of life, anti-cancer responses, breast conserving surgery and survival with neoadjuvant docetaxel: a randomised study of sequential weekly versus three-weekly docetaxel following neoadjuvant doxorubicin and cyclophosphamide in women with primary breast cancer Schematic diagram of patient entry, subsequent randomisation and treatment regimens. Rx, treatmentBack to article page